Other patients may have to do a live consult if a provider needs clarification about answers submitted in the chat consultation to ensure their treatment option is accurate, safe and effective
Therapies based on glucagon-like peptide-1 (GLP-1) reduce rates of cardiovascular and chronic kidney disease in people with type 2 diabetes and/or obesity, with ongoing clinical trials investigating their effects in people with metabolic liver disease, arthritis, and both substance use and neurodegenerative disorders
compounded medication distinctions, Wegovy pill category context, published pricing disclosures, telehealth eligibility considerations, and regulatory factors consumers are researching before choosing a GLP-1 weight loss provider San Francisco, California, Feb
The relationship between tirzepatide and migraines is not a set-it-and-forget-it situation
2026 Hillary Lin, MD All rights reserved This content is educational and isn't medical advice